QualityStocksNewsBreaks Archives - Page 636 of 1476

MondayAug 30, 2021 10:55 am

QualityStocksNewsBreaks – Ideanomics Inc. (NASDAQ: IDEX) Announces Transformative Deal to Acquire VIA Motors

Ideanomics (NASDAQ: IDEX), a global company focused on driving the adoption of commercial electric vehicles and associated energy consumption, today announced its entry into an agreement to acquire VIA Motors International Inc. (“VIA”) in an all-stock transaction for a 100% ownership stake. The transaction is subject to customary closing conditions, including Ideanomics’ shareholder approval. Headquartered in Orem, Utah, VIA will manufacture electric commercial vehicles including Class 2 through Class 5 cargo vans, trucks and buses. With deep experience in the vehicle electrification market, the company continues to develop business relationships with commercial fleets and distributors in the United States, Canada…

MondayAug 30, 2021 9:30 am

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Part 2 in ‘History of Psychedelics’ Content Series

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, partnered with Visual Capitalist to create a two-part, data-driven content series and graphic that takes a look at how psychedelics have evolved over the last 6,000 years. The second part specifically covers the psychedelic renaissance and digs deeper into what has happened to the psychedelic industry from 2017 to 2020. The two-part series captures key moments in the history of the psychedelic sector, as well as providing a brief outline of those events and the state…

FridayAug 27, 2021 1:02 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology Is ‘Outrageously Fast’ in Oral to Bloodstream Delivery

Lexaria Bioscience Corp. (NASDAQ: LEXX) on July 22 announced it had met three primary objectives in its investigation of antiviral drug conversion process outcomes as the drugs are processed with its patented DehydraTECH(TM). “The success achieved during the company’s testing paves the way for larger analysis of the DehydraTECH-processed drugs in vivo in animals infected with SARS-CoV-2/COVID-19, HIV/AIDS, or other infectious disease-causing viruses, according to the company. The ultimate aim is to form partnerships with established pharmaceutical industry drug-makers who may be interested in incorporating DehydraTECH technology with those tested drugs, or other drugs with similar characteristics,” reads a recent…

FridayAug 27, 2021 11:37 am

QualityStocksNewsBreaks – Trident Acquisitions Corp. (NASDAQ: TDAC) Files Updated Investor Presentation for Business Combination with Lottery.com

Trident (NASDAQ: TDAC, TDACU, TDACW), a special purpose acquisition company, previously announced its entry into a definitive agreement with AutoLotto Inc. (doing business as “Lottery.com”), a leading platform to play the lottery online. The agreement allows Lottery.com to become a publicly listed company. Trident today announced that it has filed an updated investor presentation with the Securities and Exchange Commission (“SEC”) in connection with its business combination with Lottery.com. The presentation includes, among other things, positive updates to peer valuation metrics and reiterates Lottery.com’s strong financial outlook and 2021 financial projections. The outlook is supported by strong preliminary second quarter…

FridayAug 27, 2021 11:17 am

QualityStocksNewsBreaks – Grapefruit USA Inc. (GPFT) Committed to Creating High-Quality Products for Its Customers, Human or Otherwise

Grapefruit USA (OTCQB: GPFT) understands that humans aren’t the only ones who may benefit from all that cannabidiol (“CBD”) has to offer and is positioning in a rapidly growing market. The pet CBD industry has experienced significant growth over the last several years, with the Brightfield Group projecting an expected market valuation of more than $1.7 billion by 2025 (https://ibn.fm/p4rDv). Grapefruit is leveraging its expertise in the space with the launch of a new USDA-certified organic CBD pet tincture. “We understand that pet owners are now demanding organic, plant-based, natural remedies to keep their furry family members calm and in…

FridayAug 27, 2021 11:02 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Eyes Fueled Mission to Develop Revolutionary Psychedelic Therapeutics

Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, in a recent historic move became the first psychedelic biotech company to trade on the NYSE American LLC stock exchange. “We are all delighted to receive this approval from the NYSE American and are thankful to our wonderful team and loyal investor base who have followed us on this journey so far,” an article quoted Cybin CEO Doug Drysdale discussing the milestone. “As the first psychedelic biotech company that will now trade on this esteemed exchange in the U.S., we will…

FridayAug 27, 2021 10:43 am

QualityStocksNewsBreaks – Brain Scientific Inc. (BRSF) Modernizing, Increasing Accessibility to Brain Diagnostics

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, is fulfilling its mission of modernizing and increasing accessibility to brain diagnostics with its FDA-cleared NeuroCap(TM) and NeuroEEG(TM), which are already patented in the United States, China and Europe. As the company’s first commercialized devices, they are designed to disrupt the current electroencephalogram (“EEG”) market by offering a cost-effective and disposable alternative to existing solutions. A recent article reads, “Brain Scientific’s development process spans three stages. The first development phase, from 2018 to 2019, resulted in the inception of the company’s portable, clinical-grade, easy-to-use neurological devices.…

FridayAug 27, 2021 10:23 am

QualityStocksNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Closes on $3M Convertible Note

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures, announced that it had secured a new convertible note totaling $3 million. Financing for the note, which was comprised of three tranches, was led by Rapha Capital BioVentures Fund I, LP (“RCBVFI”). The company anticipates using the funds to support the clinical development of its lead product, the i/Blue(TM) Imaging System. According to the company, the proprietary system is poised to increase patient access to this important technology. In addition to the funding, Imagin Medical also named Kevin…

FridayAug 27, 2021 10:05 am

QualityStocksNewsBreaks – Sustainable Green Team Ltd. (SGTM) Offering Efficient Solutions Before and After Storms

Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, and its portfolio of subsidiaries specialized in tree services, debris hauling, biomass recycling, and manufacture of next-generation mulch products and cypress lumber, have the necessary expertise to deal with storms and their negative impact. According to a recent article, SGTM’s vertically integrated operations include three brands “that speak quite clearly to the corporate mission to reduce environmental impact through responsible handling of tree debris rather than burying it in already over-burdened landfills.” The process is efficient and green. “From a mobile command…

FridayAug 27, 2021 9:38 am

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Featured in Equity Research Report

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, was featured in a recent equity research report. The coverage, initiated by Ladenburg Thalmann & Co. Inc., highlights Tryp Therapeutics’ efforts to reset the treatment of various disorders through the novel dosing of formulations of synthetic psilocybin. “We are initiating coverage on Tryp Therapeutics with a Buy rating and $2.00 price target based on our research into its psychedelic-based pipeline, which is leveraging psilocybin’s potential to treat patients with inadequately addressed neurological disorders. The company is on track to test…

Site Search

Company Search

Category: QualityStocksNewsBreaks